Repeated cannabinoid injections into the rat periaqueductal gray enhance subsequent morphine antinociception

Neuropharmacology

Volumn 55, Issue 7, 2008, Pages 1219-1225

  Wilson, Adrianne R ^a   Maher, Lauren ^a   Morgan, Michael M ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

Analgesia; Cross tolerance; Opiate; Opioid; Pain; Tolerance

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; DEXANABINOL; MORPHINE SULFATE; OPIATE;

ANALGESIA; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; CROSS TOLERANCE; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG TOLERANCE; HISTOLOGY; MALE; MICROINJECTION; NONHUMAN; PAIN; PERIAQUEDUCTAL GRAY MATTER; PRIORITY JOURNAL; RAT; SPRAGUE DAWLEY RAT;

ANALGESICS, OPIOID; ANIMALS; BEHAVIOR, ANIMAL; CANNABINOIDS; DATA INTERPRETATION, STATISTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; MALE; MICROINJECTIONS; MORPHINE; MOTOR ACTIVITY; NEUROPROTECTIVE AGENTS; PAIN MEASUREMENT; PERIAQUEDUCTAL GRAY; RATS; RATS, SPRAGUE-DAWLEY; TETRAHYDROCANNABINOL;

EID: 53949126141     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2008.07.038     Document Type: Article

References (65)

1. Basbaum A.I., and Fields H.L. Endogenous pain control systems: brainstem spinal pathways and endorphin circuitry. Annu. Rev. Neurosci. 7 (1984) 309-338
2. Bernal S.A., Morgan M.M., and Craft R.M. PAG mu opioid receptor activation underlies sex differences in morphine antinociception. Behav. Brain Res. 177 (2007) 126-133
3. Bloom A.S., and Dewey W.L. A comparison of some pharmacological actions of morphine and delta9-tetrahydrocannabinol in the mouse. Psychopharmacology (Berl.) 57 (1978) 243-248
4. Cichewicz D.L., and McCarthy E.A. Antinociceptive synergy between delta(9)-tetrahydrocannabinol and opioids after oral administration. J. Pharmacol. Exp. Ther. 304 (2003) 1010-1015
5. Cichewicz D.L., and Welch S.P. Modulation of oral morphine antinociceptive tolerance and naloxone-precipitated withdrawal signs by oral Delta 9-tetrahydrocannabinol. J. Pharmacol. Exp. Ther. 305 (2003) 812-817
6. Cichewicz D.L., Martin Z.L., Smith F.L., and Welch S.P. Enhancement mu opioid antinociception by oral delta9-tetrahydrocannabinol: dose-response analysis and receptor identification. J. Pharmacol. Exp. Ther. 289 (1999) 859-867
7. Cichewicz D.L., Welch S.P., and Smith F.L. Enhancement of transdermal fentanyl and buprenorphine antinociception by transdermal delta9-tetrahydrocannabinol. Eur. J. Pharmacol. 525 (2005) 74-82
8. Corey S. Recent developments in the therapeutic potential of cannabinoids. P. R. Health Sci. J. 24 (2005) 19-26
9. Cristino L., de Petrocellis L., Pryce G., Baker D., Guglielmotti V., and Di Marzo V. Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain. Neuroscience 139 (2006) 1405-1415
10. Dogrul A., Gul H., Akar A., Yildiz O., Bilgin F., and Guzeldemir E. Topical cannabinoid antinociception: synergy with spinal sites. Pain 105 (2003) 11-16
11. Fattore L., Vigano D., Fadda P., Rubino T., Fratta W., and Parolaro D. Bidirectional regulation of mu-opioid and CB1-cannabinoid receptor in rats self-administering heroin or WIN 55,212-2. Eur. J. Neurosci. 25 (2007) 2191-2200
12. Finn D.P., Jhaveri M.D., Beckett S.R., Roe C.H., Kendall D.A., Marsden C.A., and Chapman V. Effects of direct periaqueductal grey administration of a cannabinoid receptor agonist on nociceptive and aversive responses in rats. Neuropharmacology 45 (2003) 594-604
13. Gamble G.D., and Milne R.J. Repeated exposure to sham testing procedures reduces reflex withdrawal and hot-plate latencies: attenuation of tonic descending inhibition?. Neurosci. Lett. 96 (1989) 312-317
14. Garzon J., Rodriguez-Munoz M., Lopez-Fando A., and Sanchez-Blazquez P. Activation of mu-opioid receptors transfers control of Galpha subunits to the regulator of G-protein signaling RGS9-2: role in receptor desensitization. J. Biol. Chem. 280 (2005) 8951-8960
15. Gong J.P., Onaivi E.S., Ishiguro H., Liu Q.R., Tagliaferro P.A., Brusco A., and Uhl G.R. Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res. 1071 (2006) 10-23
16. He L., Fong J., von Zastrow M., and Whistler J.L. Regulation of opioid receptor trafficking and morphine tolerance by receptor oligomerization. Cell 108 (2002) 271-282
17. Hohmann A.G. Spinal and peripheral mechanisms of cannabinoid antinociception: behavioral, neurophysiological and neuroanatomical perspectives. Chem. Phys. Lipids 121 (2002) 173-190
18. Hohmann A.G., Tsou K., and Walker J.M. Cannabinoid suppression of noxious heat-evoked activity in wide dynamic range neurons in the lumbar dorsal horn of the rat. J. Neurophysiol. 81 (1999) 575-583
19. Hohmann A.G., Tsou K., and Walker J.M. Intrathecal cannabinoid administration suppresses noxious stimulus-evoked Fos protein-like immunoreactivity in rat spinal cord: comparison with morphine. Zhongguo Yao Li Xue Bao 20 (1999) 1132-1136
20. Hohmann A.G., Suplita R.L., Bolton N.M., Neely M.H., Fegley D., Mangieri R., Krey J.F., Walker J.M., Holmes P.V., Crystal J.D., Duranti A., Tontini A., Mor M., Tarzia G., and Piomelli D. An endocannabinoid mechanism for stress-induced analgesia. Nature 435 (2005) 1108-1112
21. Ingram S.L., Vaughan C.W., Bagley E.E., Connor M., and Christie M.J. Enhanced opioid efficacy in opioid dependence is caused by an altered signal transduction pathway. J. Neurosci. 18 (1998) 10269-10276
22. Jacquet Y.F., and Lajtha A. Paradoxical effects after microinjection of morphine in the periaqueductal gray matter in the rat. Science 185 (1974) 1055-1057
23. Jensen T.S., and Yaksh T.L. Comparison of antinociceptive action of morphine in the periaqueductal gray, medial and paramedial medulla in rat. Brain Res. 363 (1986) 99-113
24. Lane D.A., Tortorici V., and Morgan M.M. Behavioral and electrophysiological evidence for tolerance to continuous morphine administration into the ventrolateral periaqueductal gray. Neuroscience 125 (2004) 63-69
25. Lane D.A., Patel P.A., and Morgan M.M. Evidence for an intrinsic mechanism of antinociceptive tolerance within the ventrolateral periaqueductal gray of rats. Neuroscience 135 (2005) 227-234
26. Lichtman A.H., Cook S.A., and Martin B.R. Investigation of brain sites mediating cannabinoid-induced antinociception in rats: evidence supporting periaqueductal gray involvement. J. Pharmacol. Exp. Ther. 276 (1996) 585-593
27. Mailleux P., and Vanderhaeghen J.J. Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry. Neuroscience 48 (1992) 655-668
28. Manzanares J., Corchero J., Romero J., Fernandez-Ruiz J.J., Ramos J.A., and Fuentes J.A. Chronic administration of cannabinoids regulates proenkephalin mRNA levels in selected regions of the rat brain. Brain Res. Mol. Brain Res. 55 (1998) 126-132
29. Mao J., Price D.D., Lu J., Keniston L., and Mayer D.J. Two distinctive antinociceptive systems in rats with pathological pain. Neurosci. Lett. 280 (2000) 13-16
30. Martin W.J., Patrick S.L., Coffin P.O., Tsou K., and Walker J.M. An examination of the central sites of action of cannabinoid-induced antinociception in the rat. Life Sci. 56 (1995) 2103-2109
31. Martin W.J., Tsou K., and Walker J.M. Cannabinoid receptor-mediated inhibition of the rat tail-flick reflex after microinjection into the rostral ventromedial medulla. Neurosci. Lett. 242 (1998) 33-36
32. Massi P., Vaccani A., Romorini S., and Parolaro D. Comparative characterization in the rat of the interaction between cannabinoids and opiates for their immunosuppressive and analgesic effects. J. Neuroimmunol. 117 (2001) 116-124
33. Meng I.D., and Johansen J.P. Antinociception and modulation of rostral ventromedial medulla neuronal activity by local microinfusion of a cannabinoid receptor agonist. Neuroscience 124 (2004) 685-693
34. Meng I.D., Manning B.H., Martin W.J., and Fields H.L. An analgesia circuit activated by cannabinoids. Nature 395 (1998) 381-383
35. Meyer P.J., Fossum E.N., Ingram S.L., and Morgan M.M. Analgesic tolerance to microinjection of the mu-opioid agonist DAMGO into the ventrolateral periaqueductal gray. Neuropharmacology 52 (2007) 1580-1585
36. Morgan M.M., Clayton C.C., and Lane D.A. Behavioral evidence linking opioid-sensitive GABAergic neurons in the ventrolateral periaqueductal gray to morphine tolerance. Neuroscience 118 (2003) 227-232
37. Morgan M.M., Tierney B.W., and Ingram S.L. Intermittent dosing prolongs tolerance to the antinociceptive effect of morphine microinjection into the periaqueductal gray. Brain Res. 1059 (2005) 173-178
38. Morgan M.M., Fossum E.N., Levine C.S., and Ingram S.L. Antinociceptive tolerance revealed by cumulative intracranial microinjections of morphine into the periaqueductal gray in the rat. Pharmacol. Biochem. Behav. 85 (2006) 214-219
39. Morgan M.M., Fossum E.N., Stalding B.M., and King M.M. Morphine antinociceptive potency on chemical, mechanical, and thermal nociceptive tests in the rat. J. Pain 7 (2006) 358-366
40. Morgan M.M., Whitney P.K., and Gold M.S. Immobility and flight associated with antinociception produced by activation of the ventral and lateral/dorsal regions of the rat periaqueductal gray. Brain Res. 804 (1998) 159-166
41. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates (2005), Elsevier Academic Press, Amsterdam, Boston
42. Randich A., Thurston C.L., Ludwig P.S., Robertson J.D., and Rasmussen C. Intravenous morphine-induced activation of vagal afferents: peripheral, spinal, and CNS substrates mediating inhibition of spinal nociception and cardiovascular responses. J. Neurophysiol. 68 (1992) 1027-1045
43. Roberts J.D., Gennings C., and Shih M. Synergistic affective analgesic interaction between delta-9-tetrahydrocannabinol and morphine. Eur. J. Pharmacol. 530 (2006) 54-58
44. Rubino T., Tizzoni L., Vigano D., Massi P., and Parolaro D. Modulation of rat brain cannabinoid receptors after chronic morphine treatment. Neuroreport 8 (1997) 3219-3223
45. Siuciak J.A., and Advokat C. Tolerance to morphine microinjections in the periaqueductal gray (PAG) induces tolerance to systemic, but not intrathecal morphine. Brain Res. 424 (1987) 311-319
46. Smith F.L., Cichewicz D., Martin Z.L., and Welch S.P. The enhancement of morphine antinociception in mice by delta9-tetrahydrocannabinol. Pharmacol. Biochem. Behav. 60 (1998) 559-566
47. Smith P.A., Selley D.E., Sim-Selley L.J., and Welch S.P. Low dose combination of morphine and delta9-tetrahydrocannabinol circumvents antinociceptive tolerance and apparent desensitization of receptors. Eur. J. Pharmacol. 571 (2007) 129-137
48. Suzuki T., Shimada M., Yoshii T., Uesugi J., and Yanaura S. Development of physical dependence on and tolerance to morphine in rats treated with morphine-admixed food. Prog. Neuropsychopharmacol. Biol. Psychiatry 7 (1983) 63-71
49. Tallarida R.J. Drug Synergism and Dose-effect Data Analysis (2000), Chapman & Hall/CRC, Boca Raton
50. Tham S.M., Angus J.A., Tudor E.M., and Wright C.E. Synergistic and additive interactions of the cannabinoid agonist CP55,940 with mu opioid receptor and alpha2-adrenoceptor agonists in acute pain models in mice. Br. J. Pharmacol. 144 (2005) 875-884
51. Thorat S.N., and Bhargava H.N. Evidence for a bidirectional cross-tolerance between morphine and delta 9-tetrahydrocannabinol in mice. Eur. J. Pharmacol. 260 (1994) 5-13
52. Tortorici V., Robbins C.S., and Morgan M.M. Tolerance to the antinociceptive effect of morphine microinjections into the ventral but not lateral-dorsal periaqueductal gray of the rat. Behav. Neurosci. 113 (1999) 833-839
53. Trang T., Sutak M., and Jhamandas K. Involvement of cannabinoid (CB1)-receptors in the development and maintenance of opioid tolerance. Neuroscience 146 (2007) 1275-1288
54. Trujillo K.A., and Akil H. Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science 251 (1991) 85-87
55. Tsou K., Brown S., Sanudo-Pena M.C., Mackie K., and Walker J.M. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 83 (1998) 393-411
56. Valverde O., Noble F., Beslot F., Dauge V., Fournie-Zaluski M.C., and Roques B.P. Delta9-tetrahydrocannabinol releases and facilitates the effects of endogenous enkephalins: reduction in morphine withdrawal syndrome without change in rewarding effect. Eur. J. Neurosci. 13 (2001) 1816-1824
57. Vaughan C.W., Connor M., Bagley E.E., and Christie M.J. Actions of cannabinoids on membrane properties and synaptic transmission in rat periaqueductal gray neurons in vitro. Mol. Pharmacol. 57 (2000) 288-295
58. Vigano D., Rubino T., Vaccani A., Bianchessi S., Marmorato P., Castiglioni C., and Parolaro D. Molecular mechanisms involved in the asymmetric interaction between cannabinoid and opioid systems. Psychopharmacology (Berl.) 182 (2005) 527-536
59. Walker J.M., Hohmann A.G., Martin W.J., Strangman N.M., Huang S.M., and Tsou K. The neurobiology of cannabinoid analgesia. Life Sci. 65 (1999) 665-673
60. Walker J.M., Strangman N.M., and Huang S.M. Cannabinoids and pain. Pain Res. Manag. 6 (2001) 74-79
61. Welch S.P. Blockade of cannabinoid-induced antinociception by norbinaltorphimine, but not N,N-diallyl-tyrosine-Aib-phenylalanine-leucine, ICI 174,864 or naloxone in mice. J. Pharmacol. Exp. Ther. 265 (1993) 633-640
62. Welch S.P., and Stevens D.L. Antinociceptive activity of intrathecally administered cannabinoids alone, and in combination with morphine, in mice. J. Pharmacol. Exp. Ther. 262 (1992) 10-18
63. Yesilyurt O., and Dogrul A. Lack of cross-tolerance to the antinociceptive effects of systemic and topical cannabinoids in morphine-tolerant mice. Neurosci. Lett. 371 (2004) 122-127
64. Yesilyurt O., Dogrul A., Gul H., Seyrek M., Kusmez O., Ozkan Y., and Yildiz O. Topical cannabinoid enhances topical morphine antinociception. Pain 105 (2003) 303-308
65. Zambotti F., Zonta N., Parenti M., Tommasi R., Vicentini L., Conci F., and Mantegazza P. Periaqueductal gray matter involvement in the muscimol-induced decrease of morphine antinociception. Naunyn Schmiedebergs Arch. Pharmacol. 318 (1982) 368-369